{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T11:22:27Z","timestamp":1794050547935,"version":"4.8.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T00:00:00Z","timestamp":1617148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T00:00:00Z","timestamp":1617148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Clinical outcomes of pulmonary arterial hypertension (PAH) may be improved using targeted delivery system. We investigated the efficacy of ONO1301 (prostacyclin agonist) nanospheres (ONONS) in Sugen5416\/hypoxia rat models of PAH. The rats were injected with saline (control) or ONONS (n\u2009=\u200910, each) on days 21 and 28, respectively. Hepatocyte growth factor (HGF)-expressing fibroblasts and inflammatory cytokines were measured. Cardiac performance was assessed and targeted delivery was monitored in vivo, using Texas red-labeled nanoparticles. Compared with control, HGF-expressing fibroblasts and HGF expression levels were significantly higher in the ONONS group, while the levels of interleukin-6, interleukin-1\u03b2, transforming growth factor-\u03b2, and platelet-derived growth factor were lower. Histological assessment revealed significant amelioration of the percent medial wall thickness in pulmonary vasculature of rats in the ONONS group. Rats in the ONONS group showed decreased proliferating cell nuclear antigen-positive smooth muscle cells and improved right ventricle pressure\/left ventricle pressure. No difference was seen in the accumulation of Texas red-labeled nanoparticles in the brain, heart, liver, and spleen between PAH and normal rats. However, a significant area of nanoparticles was detected in the lungs of PAH rats. ONONS effectively ameliorated PAH, with selective delivery to the damaged lung.<\/jats:p>","DOI":"10.1038\/s41598-021-86781-3","type":"journal-article","created":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T10:03:51Z","timestamp":1617185031000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Innovative therapeutic strategy using prostaglandin I2 agonist (ONO1301) combined with nano drug delivery system for pulmonary arterial hypertension"],"prefix":"10.1038","volume":"11","author":[{"given":"Tomomitsu","family":"Kanaya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Miyagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuji","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiki","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Masada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobutoshi","family":"Nawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidekazu","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Narita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Toda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Kuratani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiki","family":"Sawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,31]]},"reference":[{"key":"86781_CR1","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1056\/NEJM199602013340504","volume":"334","author":"RJ Barst","year":"1996","unstructured":"Barst, R. J. et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N. Engl. Med. 334, 296\u2013301 (1996).","journal-title":"N. Engl. Med."},{"key":"86781_CR2","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1164\/rccm.200510-1668OC","volume":"173","author":"M Humbert","year":"2006","unstructured":"Humbert, M. et al. Pulmonary arterial hypertension in France: Results from a national registry. Am. J. Respir. Crit. Care Med. 173, 1023\u20131030 (2006).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"86781_CR3","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1161\/CIRCRESAHA.115.301146","volume":"115","author":"YC Lai","year":"2014","unstructured":"Lai, Y. C., Potoka, K. C., Champion, H. C., Mora, A. L. & Gladwin, M. T. Pulmonary arterial hypertension: The clinical syndrome. Circ. Res. 115, 115\u2013130 (2014).","journal-title":"Circ. Res."},{"key":"86781_CR4","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1183\/09059180.00008211","volume":"21","author":"MD McGoon","year":"2012","unstructured":"McGoon, M. D. & Miller, D. P. REVEAL: A contemporary US pulmonary arterial hypertension registry. Eur. Respir. Rev. 21, 8\u201318 (2012).","journal-title":"Eur. Respir. Rev."},{"key":"86781_CR5","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1254\/jphs.13073FP","volume":"123","author":"T Uchida","year":"2013","unstructured":"Uchida, T., Hazekawa, M., Yoshida, M., Matsumoto, K. & Sakai, Y. A novel long-acting prostacyclin agonist (ONO-1301) with an angiogenic effect: Promoting synthesis of hepatocyte growth factor and increasing cyclic AMP concentration via IP-receptor signaling. J. Pharmacol. Sci. 123, 392\u2013401 (2013).","journal-title":"J. Pharmacol. Sci."},{"key":"86781_CR6","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s10741-015-9477-8","volume":"20","author":"S Fukushima","year":"2015","unstructured":"Fukushima, S., Miyagawa, S., Sakai, Y. & Sawa, Y. A sustained-release drug-delivery system of synthetic prostacyclin agonist, ONO-1301SR: A new reagent to enhance cardiac tissue salvage and\/or regeneration in the damaged heart. Heart Fail. Rev. 20, 401\u2013413 (2015).","journal-title":"Heart Fail. Rev."},{"key":"86781_CR7","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1007\/s10753-018-0747-1","volume":"41","author":"Y Pang","year":"2018","unstructured":"Pang, Y. et al. HGF reduces disease severity and inflammation by attenuating the NF-kappaB signaling in a rat model of pulmonary artery hypertension. Inflammation 41, 924\u2013931 (2018).","journal-title":"Inflammation"},{"key":"86781_CR8","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1016\/j.addr.2013.09.019","volume":"65","author":"JL Markman","year":"2013","unstructured":"Markman, J. L., Rekechenetskiy, A., Holler, E. & Ljubimova, J. Y. Nanomedicine therapeutic approaches to overcome cancer drug resistance. Adv. Drug Deliv. Rev. 65, 1866\u20131879 (2013).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"86781_CR9","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1536\/ihj.14-150","volume":"55","author":"T Matoba","year":"2014","unstructured":"Matoba, T. & Egashira, K. Nanoparticle-mediated drug delivery system for cardiovascular disease. Int. Heart J. 55, 281\u2013286 (2014).","journal-title":"Int. Heart J."},{"key":"86781_CR10","doi-asserted-by":"publisher","first-page":"322","DOI":"10.3109\/08982100902963043","volume":"19","author":"MA Rouf","year":"2009","unstructured":"Rouf, M. A., Vural, I., Renoir, J. M. & Hincal, A. A. Development and characterization of liposomal formulations for rapamycin delivery and investigation of their antiproliferative effect on MCF7 cells. J. Liposome Res. 19, 322\u2013331 (2009).","journal-title":"J. Liposome Res."},{"key":"86781_CR11","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1172\/JCI23203","volume":"115","author":"MS McMurtry","year":"2005","unstructured":"McMurtry, M. S. et al. Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. J. Clin. Invest. 115, 1479\u20131491 (2005).","journal-title":"J. Clin. Invest."},{"key":"86781_CR12","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1378\/chest.11-0793","volume":"141","author":"LC Price","year":"2012","unstructured":"Price, L. C. et al. Inflammation in pulmonary arterial hypertension. Chest 141, 210\u2013221 (2012).","journal-title":"Chest"},{"key":"86781_CR13","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1161\/CIRCULATIONAHA.109.933762","volume":"122","author":"E Soon","year":"2010","unstructured":"Soon, E. et al. Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. Circulation 122, 920\u2013927 (2010).","journal-title":"Circulation"},{"key":"86781_CR14","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1164\/rccm.200707-1037OC","volume":"178","author":"F Perros","year":"2008","unstructured":"Perros, F. et al. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 178, 81\u201388 (2008).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"86781_CR15","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.pharmthera.2013.10.002","volume":"141","author":"D Montani","year":"2014","unstructured":"Montani, D. et al. Targeted therapies in pulmonary arterial hypertension. Pharmacol. Ther. 141, 172\u2013191 (2014).","journal-title":"Pharmacol. Ther."},{"key":"86781_CR16","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1164\/rccm.200501-102OC","volume":"172","author":"M Kataoka","year":"2005","unstructured":"Kataoka, M. et al. A long-acting prostacyclin agonist wit thromboxane inhibitory activity for pulmonary hypertension. Am. J. Respir Crit. Care Med. 172, 1575\u20131580 (2005).","journal-title":"Am. J. Respir Crit. Care Med."},{"key":"86781_CR17","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1164\/rccm.200703-349OC","volume":"177","author":"H Obata","year":"2008","unstructured":"Obata, H. et al. Single injection of a sustained-release prostacyclin analog improves pulmonary hypertension in rats. Am. J. Respir. Crit. Care Med. 177, 195\u2013201 (2008).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"86781_CR18","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1152\/ajprenal.00538.2011","volume":"302","author":"T Nasu","year":"2012","unstructured":"Nasu, T. et al. Sustained-release prostacyclin analog ONO-1301 ameliorates tubulointerstitial alterations in a mouse obstrutive nephropathy model. Am. J. Physiol. Renal. Physiol. 302, 1616\u20131629 (2012).","journal-title":"Am. J. Physiol. Renal. Physiol."},{"key":"86781_CR19","doi-asserted-by":"publisher","first-page":"e000745","DOI":"10.1161\/JAHA.112.000745","volume":"1","author":"K Kin","year":"2012","unstructured":"Kin, K. et al. Tissue- and plasma-specific microRNA signatures for atherosclerotic abdominal aortic aneurysm. J. Am. Heart Assoc. 1, e000745 (2012).","journal-title":"J. Am. Heart Assoc."},{"key":"86781_CR20","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jconrel.2014.10.029","volume":"197","author":"T Ishihara","year":"2015","unstructured":"Ishihara, T. et al. Encapsulation of beraprost sodium in nanoparticles: Analysis of sustained release properties, targeting abilities and pharmacological activities in animal models of pulmonary artery hypertension. J. Control Release. 197, 97\u2013104 (2015).","journal-title":"J. Control Release."},{"issue":"8","key":"86781_CR21","doi-asserted-by":"publisher","first-page":"e0161334","DOI":"10.1371\/journal.pone.0161334","volume":"11","author":"S Umeda","year":"2016","unstructured":"Umeda, S. et al. Enhaced pulmonary vascular alveolar development via prenatal administration of slow-release synthetic prostacyclin agonist in rat fetal lung hypoplasia. PLoS ONE 11(8), e0161334. https:\/\/doi.org\/10.1371\/journal.pone.0161334 (2016).","journal-title":"PLoS ONE"},{"key":"86781_CR22","doi-asserted-by":"publisher","first-page":"2896","DOI":"10.1161\/01.CIR.0000146342.30470.30","volume":"110","author":"M Ono","year":"2004","unstructured":"Ono, M. et al. Hepatocyte growth factor suppresses vascular medial hyperplasia and matrix accumulation in advanced pulmonary hypertension of rats. Circulation 110, 2896\u20132902 (2004).","journal-title":"Circulation"},{"key":"86781_CR23","doi-asserted-by":"publisher","first-page":"16044","DOI":"10.1038\/mtm.2016.44","volume":"3","author":"N Nawa","year":"2016","unstructured":"Nawa, N. et al. Constitutively active form of natriuretic peptide receptor 2 ameliorates experimental pulmonary arterial hypertension. Mol. Ther. Methods Clin. Dev. 3, 16044 (2016).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"86781_CR24","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.yexcr.2018.01.037","volume":"364","author":"YX Xu","year":"2018","unstructured":"Xu, Y. X. et al. Survivin regulated by autophagy mediates hyperglycemia-induced vascular endothelial cell dysfunction. Exp.. Cell Res. 364, 152\u2013159 (2018).","journal-title":"Exp.. Cell Res."},{"key":"86781_CR25","first-page":"318","volume":"4","author":"S Yajima","year":"2019","unstructured":"Yajima, S. et al. Prostacyclin analogue-loaded nanoparticles attenuate myocardial ischemia\/reperfusion injury in rats. JACC. 4, 318\u2013331 (2019).","journal-title":"JACC."},{"key":"86781_CR26","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1161\/CIRCULATIONAHA.109.927681","volume":"121","author":"K Abe","year":"2010","unstructured":"Abe, K. et al. Formation of plexiform lesions in experimental severe pulmonary arterial hypertension. Circulation 121, 2747\u20132754 (2010).","journal-title":"Circulation"},{"key":"86781_CR27","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1164\/rccm.200702-264OC","volume":"177","author":"F Kamezaki","year":"2008","unstructured":"Kamezaki, F. et al. Gene transfer o extracellular superoxide dismutase ameliolates pulmonary hypertension in rats. Am. J. Respir. Crit. Care Med. 177, 219\u2013226 (2008).","journal-title":"Am. J. Respir. Crit. Care Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-86781-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-86781-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-86781-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T06:13:32Z","timestamp":1670048012000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-86781-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,31]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["86781"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-86781-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,31]]},"assertion":[{"value":"4 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7292"}}